PMID- 21269783
OWN - NLM
STAT- MEDLINE
DCOM- 20120113
LR  - 20211020
IS  - 1879-0046 (Electronic)
IS  - 0376-8716 (Print)
IS  - 0376-8716 (Linking)
VI  - 116
IP  - 1-3
DP  - 2011 Jul 1
TI  - 3,4-Methylenedioxymethamphetamine (MDMA) alters acute gammaherpesvirus burden and 
      limits interleukin 27 responses in a mouse model of viral infection.
PG  - 211-21
LID - 10.1016/j.drugalcdep.2010.12.019 [doi]
AB  - AIMS: To test whether 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") abuse 
      might increase the susceptibility, or alter the immune response, to murine 
      gammaherpesvirus 68 (HV-68) and/or bacterial lipopolysaccharide. METHODS: Groups 
      of experimental and control mice were subjected to three day binges of MDMA, and 
      the effect of this drug abuse on acute and latent HV-68 viral burden were 
      assessed. In vitro and in vivo studies were also performed to assess the MDMA 
      effect on IL-27 expression in virally infected or LPS-exposed macrophages and 
      dendritic cells, and latently infected animals, exposed to this drug of abuse. 
      RESULTS: Acute viral burden was significantly increased in MDMA-treated mice when 
      compared to controls. However the latent viral burden, and physiological and 
      behavioral responses were not altered in infected mice despite repeated bingeing 
      with MDMA. MDMA could limit the IL-27 response of HV-68 infected or LPS-exposed 
      macrophages and dendritic cells in vitro and in vivo, demonstrating the ability 
      of this drug to alter normal cytokine responses in the context of a viral 
      infection and/or a TLR4 agonist. CONCLUSION: MDMA bingeing could alter the host's 
      immune response resulting in greater acute viral replication and reductions in 
      the production of the cytokine, IL-27 during immune responses.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Nelson, Daniel A
AU  - Nelson DA
AD  - Department of Biology, University of North Carolina at Charlotte, Charlotte, NC 
      28223, USA.
FAU - Singh, Sam J
AU  - Singh SJ
FAU - Young, Amy B
AU  - Young AB
FAU - Tolbert, Melanie D
AU  - Tolbert MD
FAU - Bost, Kenneth L
AU  - Bost KL
LA  - eng
GR  - R01 DA021833/DA/NIDA NIH HHS/United States
GR  - R01 DA021833-04/DA/NIDA NIH HHS/United States
GR  - R01 DA DA021833/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110126
PL  - Ireland
TA  - Drug Alcohol Depend
JT  - Drug and alcohol dependence
JID - 7513587
RN  - 0 (Hallucinogens)
RN  - 0 (Interleukin-17)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Tlr4 protein, mouse)
RN  - 0 (Toll-Like Receptor 4)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Dendritic Cells/drug effects
MH  - Disease Models, Animal
MH  - Female
MH  - Gammaherpesvirinae/drug effects/genetics/immunology
MH  - Hallucinogens/*pharmacology
MH  - Herpesviridae Infections/immunology/metabolism/*virology
MH  - Interleukin-17/antagonists & inhibitors/*metabolism
MH  - Lipopolysaccharides/immunology
MH  - Macrophages/drug effects
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Toll-Like Receptor 4/agonists
MH  - Viral Load/*drug effects/immunology
PMC - PMC3105168
MID - NIHMS265022
COIS- Conflict of interest All authors declare that they have no conflicts of interest.
EDAT- 2011/01/29 06:00
MHDA- 2012/01/14 06:00
PMCR- 2012/07/01
CRDT- 2011/01/29 06:00
PHST- 2010/07/08 00:00 [received]
PHST- 2010/10/12 00:00 [revised]
PHST- 2010/12/29 00:00 [accepted]
PHST- 2011/01/29 06:00 [entrez]
PHST- 2011/01/29 06:00 [pubmed]
PHST- 2012/01/14 06:00 [medline]
PHST- 2012/07/01 00:00 [pmc-release]
AID - S0376-8716(11)00041-X [pii]
AID - 10.1016/j.drugalcdep.2010.12.019 [doi]
PST - ppublish
SO  - Drug Alcohol Depend. 2011 Jul 1;116(1-3):211-21. doi: 
      10.1016/j.drugalcdep.2010.12.019. Epub 2011 Jan 26.